LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

LLY

1,011.27

-2.12%↓

JNJ

243.2

-0.52%↓

ABBV

223.56

-2.05%↓

NVS

165.44

-1.33%↓

MRK

119.45

-2.56%↓

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

28.2 -0.81

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.62

Max

28.73

Pagrindiniai rodikliai
By Trading Economics
Pajamos	11M 51M
Pardavimai	39M 239M
P/E Sektoriaus vid.	8.476 108.767
Pelnas, tenkantis vienai akcijai	1.08
Pelno marža	21.242
Darbuotojai	268
EBITDA	14M 73M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+46.33% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-140M 1.5B
Ankstesnė atidarymo kaina	29.01
Ankstesnė uždarymo kaina	28.2

Naujienos nuotaikos

By Acuity

34%

66%

108 / 351 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-25 23:25; UTC

Karštos akcijos

Stocks to Watch: C3.ai, Salesforce, Pure Storage, Zoom

2026-02-25 23:15; UTC

Uždarbis

Salesforce Sees Stable Growth; CEO Dismisses Talk of AI-Fueled 'SaaS-Pocalypse' -- 2nd Update

2026-02-25 23:54; UTC

Rinkos pokalbiai

Gold Steady Ahead of U.S.-Iran Talks -- Market Talk

2026-02-25 23:47; UTC

Uždarbis

Ferrovial 4Q Net EUR197M >FER.MC

2026-02-25 23:45; UTC

Uždarbis

Ferrovial 4Q Rev EUR2.72B >FER.MC

2026-02-25 23:42; UTC

Uždarbis

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 4th Update

2026-02-25 23:38; UTC

Rinkos pokalbiai

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Company's Business Operations Remain Normal >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Gives Update on Investigation by China's State Administration for Market Regulation >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Cannot Predict Status or Results of Investigation, Will Provide Updates on Conclusion >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Increase in FY Profit Primarily Due to Gain From Investments >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Will Continue to Communicate With SAMR on Compliance With Regulatory Requirements >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: SAMR Investigation Related to China's Anti-monopoly Law >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Investigation Ongoing, Company Is Cooperating With SAMR >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com Co-founders Min Fan, Qi Ji Resign From Positions >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com: Fan Resigned as Director and President; Ji Resigned as a Director >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com FY Rev CNY62.4B, Up 17% >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com FY Net CNY33.3B Vs. Net CNY17.1B >TCOM

2026-02-25 23:25; UTC

Uždarbis

Trip.com FY EPS CNY47.67 >TCOM

2026-02-25 23:06; UTC

Uždarbis

Correction to Nvidia Fourth Quarter Results Article -- WSJ

2026-02-25 23:01; UTC

Uždarbis

Nvidia Beats Back Bubble Fears With Record $68 Billion Sales in Fourth Quarter -- 3rd Update

2026-02-25 23:00; UTC

Rinkos pokalbiai

Uždarbis

Global Equities Roundup: Market Talk

2026-02-25 23:00; UTC

Rinkos pokalbiai

Uždarbis

Nvidia: Chinese Competitors Pose Risk to U.S. Dominance in AI -- Market Talk

2026-02-25 22:56; UTC

Rinkos pokalbiai

Uždarbis

Nvidia CEO Says Customers Can't Grow Revenue Without Compute -- Market Talk

2026-02-25 22:43; UTC

Uždarbis

Įsigijimai, susijungimai, perėmimai

Paramount Streaming Revenue Rises, but TV Segment Faces Headwinds -- WSJ

2026-02-25 22:40; UTC

Rinkos pokalbiai

Uždarbis

Nvidia Says Agentic AI Has Reached Inflection Point -- Market Talk

2026-02-25 22:40; UTC

Uždarbis

Karoon Energy Says Search for New CFO Well Advanced

2026-02-25 22:39; UTC

Uždarbis

Karoon Energy Says CFO Ray Church to Leave Company

2026-02-25 22:39; UTC

Uždarbis

Karoon Energy Says On-Market Share Buyback Program Ongoing at Moderated Level

2026-02-25 22:38; UTC

Uždarbis

Karoon Energy Says Guidance for 2026 Key Metrics Unchanged

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

46.33% į viršų

12 mėnesių prognozė

Vidutinis 41.25 USD 46.33%

Aukščiausias 62 USD

Žemiausias 25 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

108 / 351 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.